search

Medical & Bio Decision (MBD) provides a 3D cell culture platform specialised in anticancer drug sensitivity. The company’s relationship with Luxembourg started in 2017 when it first sold its medical devices to a hospital here. An invitation to participate in a collaborative research project with a French research centre and the Luxembourg Institute of Health then spurred on discussions regarding longer-term research cooperation.

Exploring Luxembourg

“MBD initially considered locating its European office in France or Germany since it has several customers there,” explains Younhee Kim, Executive Director of the Luxembourg Trade and Investment Office (LTIO) in Seoul, who has supported the company throughout the process. “However, the contacts with the CEO of LIH and Dr Yong-Jun Kwon, who heads the Early Drug Discovery Platform of the Personalized Drug Discovery research group at the LIH Department of Oncology, were instrumental in increasing the company interest to set up an office in Luxembourg.”

The LTIO provided MBD with tailor-made information on the Luxembourg business environment and company incorporation process, as well as on topics such as taxation, the education system and the cost of living. Together with the Ministry of the Economy and the House of Entrepreneurship, the LTIO also helped the MBD management meet with start-up incubators and relevant healthtech players during a visit to Luxembourg in February 2020.

Translational oncology research

MBD announced its decision to set up a joint laboratory with LIH in December 2020. “We selected LIH as our business partner because the institute understands MBD’s technology and vision very well since we have been working with the CEO and with Dr Kwon for a long time,” comments MBD’s CEO Bosung Ku.

The laboratory, which is located at the premises of IBBL in Dudelange in the south of the country, will focus on performing translational oncology research. LIH explains that the 3D cell culture chip developed by MBD makes it possible to identify the most effective anticancer drug using cancer cells derived directly from patients. This innovative three-dimensional solution overcomes some of the issues associated with 2D cultures by providing a more accurate and physiologically relevant tissue model, thereby enabling a more precise prediction of a drug’s efficacy and toxicity profile and supporting next-generation drug screening and development.

Our collaboration will advance precision oncology for the benefit of patients in Luxembourg, Europe and worldwide.

The lab will use samples from cancer patients across Europe and will leverage IBBL’s state-of-the-art biological sample storage facilities. “Our collaboration will advance precision oncology for the benefit of patients in Luxembourg, Europe and worldwide”, explains Dr Kwon.

European expansion

MBD considers the Grand Duchy as an ideal place to grow. “Luxembourg has a favourable business environment and is geographically in the centre of Europe,” comments Mr Ku. “I think it is a very good location for attracting highly skilled staff from France and Germany.”

Luxembourg has a favourable business environment and is geographically in the centre of Europe.

With the MBD-LIH joint lab up and running, the company is now also planning to benefit from its Luxembourg branch to increase its business reach. “We would like to expand our promotion and network throughout Europe and well beyond,” says Mr Ku.

Read more

Luxembourg remains a strong innovator

27-09-2022

Luxembourg remains the 7th best-performing EU country in the 2022 edition of the European Innovation Scoreboard and continues to stand out for its highly attractive research system.
Read more

Previsionz expands to Luxembourg

23-09-2022

German-born Previsionz is one of the recent additions to Luxembourg’s data ecosystem. Supported by Luxinnovation, the data analytics company has chosen Luxembourg as its springboard for international growth.
Read more

Luxembourg 13th most competitive country in the world

13-09-2022

Luxembourg is ranked as the world’s 13th most competitive country in the 2022 edition of the IMD World Competitiveness Ranking. The country ranks 1st in the world for its economic performance.
Read more

Luxembourg among top 10 countries for post-COVID FDI recovery

12-09-2022

Foreign direct investment in Luxembourg increased by 85% during the first half of 2022, compared to the first 6 months of 2019.
Read more

Luxembourg economy 3rd most resilient in the world

07-09-2022

Luxembourg remains the world's 3rd most resilient economy in the 2022 FM Global Resilience Index. The country even strengthens its global score compared to last year.
Read more

Resources all news

Fermer